Canada's Xenon Pharma Q2 net loss widens on higher expenses
XENE•Outlook
- Xenon expects to submit NDA for azetukalner in FOS in Q3 2026
- Topline Phase 3 X-NOVA2 data in MDD expected in H1 2027
- Company expects cash runway to fund operations into 2029
Result drivers
- R&D spend - Higher research and development expenses driven by ongoing Phase 3 clinical studies for azetukalner and manufacturing activities for planned NDA submission
- Admin costs - Higher general and administrative expenses due to increased personnel-related costs and professional and consulting fees
- Collaboration revenue - Lower revenue from Neurocrine Biosciences collaboration contributed to wider net loss
Q2 net loss widens
- Canada neuroscience drug developer's Q2 net loss widened and missed analyst expectations
- Higher R&D and administrative costs drove the increased net loss in the quarter
- Company ended Q2 with $1.2 bln in cash and expects runway into 2029
Key details and analyst coverage
| Metric |
|---|
